Form 4: Kineta Director Scott Dylla Reports Share Disposition and Option Changes Following TuHURA Biosciences Merger

Kineta, Inc. Director Scott J. Dylla reported the disposition of 17,794 common shares and the cancellation of certain stock options, along with the vesting of others, as a result of Kineta's merger with TuHURA Biosciences, Inc.

Summary

• Scott J. Dylla, a Director of Kineta, Inc., reported changes in his beneficial ownership due to the merger of Kineta, Inc. with TuHURA Biosciences, Inc.
• 17,794 shares of Kineta Common Stock were disposed of on June 30, 2025, as part of the merger agreement.
• Each outstanding share of Kineta Common Stock was cancelled and converted into the right to receive 0.185298 shares of TuHURA Common Stock.
• Kineta stockholders are also entitled to a pro rata portion of 1,129,884 shares of TuHURA Common Stock to be issued six months post-merger, subject to adjustment for losses incurred or accrued during that period.
• Additionally, Kineta stockholders will receive a pro rata share of cash consideration from disposed legacy Kineta assets.
• Stock options with an exercise price greater than $0.64 were canceled and extinguished for no consideration at the effective time of the merger, including 20,000 options with an exercise price of $2.58.
• 12,500 stock options with an exercise price of $0.611 became fully vested on June 23, 2025, pursuant to an Optionholder Treatment Agreement and the Merger Agreement, and were subsequently disposed of.
• This Form 4 amends a previous filing from June 25, 2025, to correct misreported share and derivative security amounts.

Sentiment

Score: 6

Explanation: The document reports the expected outcome of a merger, which includes both positive aspects (vesting of some options, receipt of new shares and potential cash) and negative aspects (cancellation of out-of-the-money options, complete disposition of prior holdings). The correction of a previous filing indicates a commitment to accuracy, which is positive for transparency.

Positives

• 12,500 stock options with an exercise price of $0.611 became fully vested on June 23, 2025, prior to their disposition in the merger.
• Kineta shareholders receive TuHURA Common Stock (0.185298 shares per Kineta share) plus potential additional TuHURA shares (pro rata portion of 1,129,884 shares) and cash from legacy asset dispositions.

Negatives

• Stock options with an exercise price greater than $0.64 were canceled for no consideration, resulting in a loss of potential value for the holder, such as 20,000 options at a $2.58 exercise price.
• The reporting person disposed of all Kineta common stock and derivative securities as a result of the merger.

Future Outlook

Kineta stockholders are expected to receive a pro rata portion of 1,129,884 shares of TuHURA Common Stock six months following the closing of the mergers, subject to adjustment for losses, and a pro rata share of cash consideration from disposed legacy Kineta assets.

Industry Context

This Form 4 reflects the final stages of a corporate merger, a common strategic move in the biotechnology and pharmaceutical sectors for companies seeking to combine assets, pipelines, or market reach, often involving a smaller entity being acquired by or merging into a larger or more stable one.

Stakeholder Impact

• Shareholders (Kineta): Their shares were converted into TuHURA Common Stock, with potential for additional shares and cash, but also faced cancellation of certain options.
• Shareholders (TuHURA): Their company acquired Kineta, potentially expanding their business.

Next Steps

• Issuance of pro rata portion of 1,129,884 shares of TuHURA Common Stock to Kineta stockholders six months following the closing of the mergers.
• Distribution of pro rata share of cash consideration from disposed legacy Kineta assets to Kineta stockholders.

Key Dates

Keywords

SEC Form 4, Kineta Inc., TuHURA Biosciences Inc., Merger, Stock Options, Common Stock, Beneficial Ownership, KANT, Corporate Transaction, Director Holdings, Equity Incentive Plan